Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 100.28
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell